Compare · CYTK vs NVO
CYTK vs NVO
Side-by-side comparison of Cytokinetics Incorporated (CYTK) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CYTK and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 22.3x CYTK ($9.98B).
- Over the past year, CYTK is up 115.2% and NVO is down 21.8% - CYTK leads by 137.0 points.
- CYTK has been more active in the news (18 items in the past 4 weeks vs 5 for NVO).
- Both have 25 recent analyst ratings on file.
- Company
- Cytokinetics Incorporated
- Novo Nordisk A/S
- Price
- $80.15-0.23%
- $50.31-2.25%
- Market cap
- $9.98B
- $222.81B
- 1M return
- +6.61%
- +15.47%
- 1Y return
- +115.23%
- -21.78%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2004
- News (4w)
- 18
- 5
- Recent ratings
- 25
- 25
Cytokinetics Incorporated
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops reldesemtiv that is in Phase II clinical trials in patients with chronic obstructive pulmonary disease, and in Phase Ib clinical trials in elderly subjects with limited mobility. In addition, it develops CK-3773274 (CK-274), a novel cardiac myosin inhibitor, which is in Phase II clinical trial for the potential treatment of hypertrophic cardiomyopathy; CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and CK-3772271 (CK-271), a novel cardiac myosin inhibitor that is in Phase I clinical trial. The company has a strategic alliance with Astellas Pharma Inc. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CYTK
- Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Director Wysenski Nancy was granted 75 shares, increasing direct ownership by 0.22% to 33,992 units (SEC Form 4)
- Director Wierenga Wendell was granted 75 shares, increasing direct ownership by 0.21% to 35,563 units (SEC Form 4)
- Director Kaye Edward M. Md was granted 151 shares, increasing direct ownership by 1% to 10,434 units (SEC Form 4)
- Director Henderson John T was granted 272 shares, increasing direct ownership by 0.35% to 78,360 units (SEC Form 4)
- Director Harrington Robert Arthur was granted 151 shares, increasing direct ownership by 0.69% to 21,932 units (SEC Form 4)
- Director Daly James M was granted 151 shares, increasing direct ownership by 5% to 3,390 units (SEC Form 4)
- President & CEO Blum Robert I sold $615,150 worth of shares (7,500 units at $82.02) and exercised 7,490 shares at a strike of $10.60, decreasing direct ownership by 0.00% to 377,820 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Cytokinetics Incorporated
- EVP Research & Development Malik Fady Ibraham exercised 3,500 shares at a strike of $7.80 and sold $303,170 worth of shares (3,500 units at $86.62) (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S